<DOC>
	<DOCNO>NCT03084679</DOCNO>
	<brief_summary>The investigator hypothesise novel MRI metric derive myocardium post-gadolinium T1 mapping analysis improve current knowledge role interstitial fibrosis cardiomyocyte hypertrophy development leave ventricular ( LV ) remodelling clinical Heart Failure ( HF ) . The investigator believe recently describe variable associate prognostically important index HF development .</brief_summary>
	<brief_title>Characterization Myocardial Interstitial Fibrosis Cardiomyocyte Hypertrophy Cardiac MRI Heart Failure</brief_title>
	<detailed_description>Cardiac hypertrophy one early manifestation myocardial disease , represent modifiable , prognostic response hemodynamic stimulus across physiologic ( e.g. , exercise ) pathologic state ( e.g. , hypertension , aortic stenosis ) . The extent myocardial hypertrophy determine combination cardiomyocyte size extracellular volume ( ECV ) expansion/interstitial fibrosis : physiologic ( exercise-induced ) hypertrophy reflect mostly reversible cardiomyocyte hypertrophy , pathologic hypertrophy ( e.g. , heart failure ) combination interstitial fibrosis ( potentially irreversible ) cardiomyocyte hypertrophy ( reversible ) . Current method delineate potential LV reverse remodeling ( e.g. , natriuretic peptide echocardiographic clinical marker ) detect primarily advanced disease , miss critical opportunity intervene follow patient early disease phase myocardial pathology may reversible . Therefore , establish novel , quantitative metric myocardial tissue phenotype define transition hypertrophy fibrosis , irreversible LV remodeling/dysfunction may facilitate target therapy modifiable stage disease HF . The investigator 's group recently extend cardiac T1 mapping MRI techniques quantify intracellular lifetime water ( Ï„ic ) serially index cardiomyocyte diameter , validate technique histologically mouse model pressure overload .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>Age &gt; 18 year Functional limitation ( New York Heart Association Class II worse ) No contraindication exercise ( American College Cardiology / American Heart Association criterion ) Eligibility take MRI ( absence metallic device , glomerular filtration rate &gt; 40ml / min / 1.73m2 , etc . ) Prior diagnosis Heart Failure ( Framingham criterion ) Therapy diuretic euvolemia state ( evaluated cardiologist cardiopulmonary exercise test ) Transthoracic echocardiogram Severe ischemia stress test Hypertrophic cardiomyopathy infiltrative heart disease Chronic obstructive pulmonary disease , pulmonary hypertension ( Pulmonary artery pressure &gt; 60mmHg ) Severe leave right valve disease . Pacemaker implantable cardioverter defibrillator Myocardial infarction revascularization 3 month Anemia ( hemoglobin &lt; 10 gram / dl ) 1 month cardiopulmonary exercise testing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Hypertrophy</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Magnetic Resonance</keyword>
</DOC>